Clinical Trial Update: Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca [Phase 2]

View source ↗

Summary

Phase II trial of Allo LMI vaccine with IL-2 for stable metastatic breast cancer was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Allo LMI vaccine with IL-2

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-06-06